Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04112095 · ClinicalTrials.gov registry record · Phase 3
Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
A Phase 3 study, sponsored by HRA Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 962
- Enrollment target
NCT04112095 is a Phase 3 study that has completed, run by HRA Pharma. The registered enrollment target is 962 participants.
The verdict
NCT04112095, a Phase 3 study, has completed, sponsored by HRA Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 962 participants
- Enrollment target
Study Summary
This study is designed to assess whether consumers select and use norgestrel 0.075 mg, a progestin only pill for contraception, in a manner consistent with the OTC package directions in an Over-the-Counter (OTC)-like setting.
Interventions
- DRUG Norgestrel 0.075 mg tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 962 participants |
| Start Date | 2019-09-06 |
| Est. Completion | 2021-08-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04112095
The ClinicalTrials.gov registry entry for NCT04112095 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 962 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HRA Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Norgestrel 0.075 mg tablets is the first listed.
NCT04112095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04112095 about?
NCT04112095 is a clinical study titled "Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use". This study is designed to assess whether consumers select and use norgestrel 0.075 mg, a progestin only pill for contraception, in a manner consistent with the OTC package directions in an Over-the-Counter (OTC)-like setting.
What is the current status of trial NCT04112095?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 962 participants. The study started on 2019-09-06. Estimated completion is 2021-08-05.
What interventions are being tested in trial NCT04112095?
The interventions under investigation include: Norgestrel 0.075 mg tablets (DRUG).
Who is sponsoring clinical trial NCT04112095?
This trial is sponsored by HRA Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.